Table 5 PCDHAC2, PCDHGC5 and PCDH10 methylation status according to clinicopathological features of patients (n = 23)
Sample ID | Age range (yr) | Tumor stage | Methylation status (%) | ||
|---|---|---|---|---|---|
PCDHAC2 | PCDHGC5 | PCDH10 | |||
PKCH2207 T | 65–70 | 0 | 100 | 0 | |
PKCH2007 T | 60–65 | II | 0 | 100 | 0 |
PKCH2807 T | 55–60 | III | 0 | 100 | 0 |
PKCH2908 T | 75–80 | III | 0 | 100 | 0 |
PKCH3708 T | 45–50 | III | 0 | 100 | 0 |
PKCH3808 T | 75–80 | III | 0 | 100 | 0 |
PKCH12411 T | 55–60 | 0 | 100 | 50 | |
PKCH13311 T | 65–70 | III | 0 | 100 | 50 |
PKCH2607 T | 75–80 | II | 0 | 100 | 50 |
PKCH2507 T | 70–75 | III | 0 | 100 | 50 |
PKCH3408 T | 75–80 | III | 0 | 100 | 55 |
PKCH21913 T | 60–65 | III | 0 | ||
PKCH5309 T | 50–55 | II | 0 | ||
PKCH20212 T | 55–60 | III | 0 | ||
PKCH17112 T | 70–75 | III | 8 | ||
PKCH14511 T | 50–55 | III | 9 | ||
PKCH20712 T | 70–75 | II | 9 | ||
PKCH17612 T | 55–60 | III | 65 | ||
PKCH14111 T | 65–70 | II | 80 | ||
PKCH10410 T | 70–75 | III | 83 | ||
PKCH8510 T | 45–50 | III | 80 | ||
PKCH9610 T | 70–75 | III | 90 | ||
PKCH15511 T | 35–40 | II | 91 | ||